Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-005-0077-y.pdf
Reference56 articles.
1. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–1512. Report on the TAX327 trial, presented at ASCO 2004, and discussed further in the text.
2. Petrylak DP, Tangen CM, Hussain MHA, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–1520. SWOG 9916 was presented at ASCO 2004 and is discussed further in the text.
3. Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999, 17:2506–2513.
4. Bubley GJ, Carducci MA, Dahut W, et al.: Eligibility and response guidelines for phase III clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 1999, 17:3461–3467.
5. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591–1597. One of the largest natural history studies of men who relapse following radical prostatectomy. It provides the basis for many of the estimates regarding time to progression, mortality, and development of metastatic disease in this heterogeneous population.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 –2018);Frontiers in Oncology;2023-06-09
2. Inhibition of prostate cancer growth by immunization with a GM-CSF-modified mouse prostate cancer RM‑1 cell vaccine in a novel murine model;Oncology Letters;2017-11-02
3. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer;Urologic Oncology: Seminars and Original Investigations;2017-01
4. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP);Prostate Cancer and Prostatic Diseases;2010-11-02
5. Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer;Cancer Biology & Therapy;2007-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3